Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.47 |
| ▸ | HTR2C | P28335 | 3/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14312363 | 1.00 | HTR2A (0.47) | HTR2AHTR2CMAPK14HDAC2HDAC1 | |
| SCHEMBL14312206 | 0.91 | HTR2A (0.47) | HTR2AHTR2CMAPK14HDAC2HDAC1 | |
| SCHEMBL2443370 | 0.91 | HTR2A (0.47) | HTR2AHTR2CMAPK14HDAC2HDAC1 | |
| SCHEMBL14312294 | 0.89 | HTR2A (0.48) | HTR2AHTR2CMAPK14HDAC2HDAC1 | |
| SCHEMBL2446573 | 0.89 | HTR2A (0.48) | HTR2AHTR2CMAPK14HDAC2HDAC1 | |
| SCHEMBL14312184 | 0.88 | HTR2A (0.43) | HTR2AHTR2CMAPK14HDAC2HDAC1 | |
| SCHEMBL2450214 | 0.88 | HTR2A (0.43) | HTR2AHTR2CMAPK14HDAC2HDAC1 | |
| SCHEMBL2447222 | 0.87 | HTR2A (0.51) | HTR2AHTR2CMAPK14HDAC2HDAC1 | |
| SCHEMBL2447221 | 0.87 | HTR2A (0.51) | HTR2AHTR2CMAPK14HDAC2HDAC1 | |
| SCHEMBL2442970 | 0.82 | MAPK14 (0.44) | HTR2AHTR2CMAPK14HDAC2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518983-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2013-08-27 | — | — | US | claimed |
| EP-2039685-B1 | Heterobicyclic compounds as P38 inhibitors | ARRAY BIOPHARMA INC (US) | 2012-12-26 | — | — | EP | claimed |
| EP-1997809-B1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC (US) | 2014-05-14 | — | — | EP | disclosed |
| US-8518983-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-1997810-B1 | Indazoles, benzotriazoles and N-analogs thereof as p38 kinase inhibitors | ARRAY BIOPHARMA INC (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2039685-B1 | Heterobicyclic compounds as P38 inhibitors | ARRAY BIOPHARMA INC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8017641-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-7799782-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090149459-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090143422-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090136596-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-05-28 | — | — | US | disclosed |
| EP-1997810-A2 | Indazole, benzoxazole and pyrazolopyridine derivatives for medical use | Array Biopharma Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1997809-A2 | Indazole, benzoxazole and pyrazolopyridine derivatives for medical use | Array Biopharma Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1606283-A4 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2007-05-23 | — | — | EP | disclosed |
| US-7135575-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA, INC. (US) | 2006-11-14 | — | — | US | disclosed |
| EP-1606283-A2 | P38 INHIBITORS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20040192653-A1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. | 2004-09-30 | — | — | US | disclosed |
| US-20040180896-A1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA, INC. | 2004-09-16 | — | — | US | disclosed |
| WO-2004078116-A2 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20040176325-A1 | P38 MAP kinase inhibitors comprising indazole derivatives; antiinflammatory and antiproliferative agents; autoimmune, bone, and neurodegenerative disorders; viricides, infections | ARRAY BIOPHARMA INC. | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143422-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | MAPKAPK2, MAPK1, MAPK8 | HTR2A 3533/4885HTR2C 3263/4885MAPK14 37/4885 |
| US-20040176325-A1 | P38 MAP kinase inhibitors comprising indazole derivatives; antiinflammatory and antiproliferative agents; autoimmune, bone, and neurodegenerative disorders; viricides, infections | MAPK1, MAPK3, MAP3K1 | HTR2A 4514/4885HTR2C 4472/4885MAPK14 29/4885 |
| US-20090136596-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | MAPKAPK2, MAPK1, MAPK8 | HTR2A 3533/4885HTR2C 3263/4885MAPK14 37/4885 |
| US-20090149459-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | MAPKAPK2, MAPK1, MAPK8 | HTR2A 3533/4885HTR2C 3263/4885MAPK14 37/4885 |
| US-20040180896-A1 | P38 inhibitors and methods of use thereof | MAPK1, MAPK3, MAPK8 | HTR2A 3462/4885HTR2C 3240/4885MAPK14 39/4885 |
| US-20040192653-A1 | P38 inhibitors and methods of use thereof | MAPK1, MAPK3, MAPK8 | HTR2A 3462/4885HTR2C 3240/4885MAPK14 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.